AVXL — Anavex Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $771.33m
- $670.16m
- 37
- 17
- 78
- 39
Annual cashflow statement for Anavex Life Sciences, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -26.3 | -37.9 | -48 | -47.5 | -43 |
| Non-Cash Items | 4.88 | 8.23 | 18.4 | 17.2 | 9.44 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.117 | -0.706 | 5.36 | 2.5 | 2.75 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -21.3 | -30.4 | -24.2 | -27.8 | -30.8 |
| Financing Cash Flow Items | -0.404 | -5.55 | -0.707 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 28.4 | 153 | 21.3 | 29.7 | 12 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.06 | 123 | -2.95 | 1.87 | -18.8 |